Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | MMP9 | P14780 | 2/20 | 0.48 |
| ▸ | MMP8 | P22894 | 2/20 | 0.48 |
| ▸ | CTSS | P25774 | 4/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | CDC25A | P30304 | 1/20 | 0.45 |
| ▸ | CDC25B | P30305 | 1/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18558745 | 1.00 | SYK (0.53) | SYKPPARAMMP9MMP8CTSS | |
| SCHEMBL19853304 | 1.00 | SYK (0.53) | SYKPPARAMMP9MMP8CTSS | |
| SCHEMBL19614435 | 1.00 | SYK (0.53) | SYKPPARAMMP9MMP8CTSS | |
| SCHEMBL19602411 | 0.93 | PPARA (0.47) | SYKPPARAMMP9MMP8CTSS | |
| SCHEMBL24814238 | 0.93 | KLK5 (0.54) | SYKPPARAMMP9MMP8CTSS | |
| SCHEMBL9545042 | 0.93 | KLK5 (0.54) | SYKPPARAMMP9MMP8CTSS | |
| SCHEMBL30751650 | 0.93 | KLK5 (0.54) | SYKPPARAMMP9MMP8CTSS | |
| SCHEMBL9545038 | 0.93 | KLK5 (0.54) | SYKPPARAMMP9MMP8CTSS | |
| SCHEMBL6387553 | 0.90 | PPARA (0.48) | SYKPPARAMMP9MMP8CTSS | |
| SCHEMBL1414711 | 0.90 | PPARA (0.55) | SYKPPARAMMP9MMP8CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002495-A1 | SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME | TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) | 2025-01-02 | — | — | US | disclosed |
| US-12157736-B2 | Spiro-lactam NMDA modulators and methods of using same | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2024-12-03 | — | — | US | disclosed |
| US-12084444-B2 | Spiro-lactam NMDA modulators and methods of using same | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (CN) | 2024-09-10 | — | — | US | disclosed |
| WO-2024054919-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (CN) | 2024-03-14 | — | — | WO | disclosed |
| EP-3490994-B1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-3490990-B1 | SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME | TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) | 2023-12-06 | — | — | EP | disclosed |
| US-20230192693-A1 | SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2023-06-22 | — | — | US | disclosed |
| US-20230128006-A1 | SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME | APTINYX INC. | 2023-04-27 | — | — | US | disclosed |
| US-11427585-B2 | Spiro-lactam NMDA modulators and methods of using same | APTINYX INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-11370790-B2 | Spiro-lactam NMDA modulators and methods of using same | APTINYX INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-10196401-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10195179-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10150769-B2 | Spiro-lactam NMDA modulators and methods of using same | APTINYX INC. (US) | 2018-12-11 | — | — | US | disclosed |
| US-20180291023-A1 | SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-10-11 | — | — | US | disclosed |
| US-20180092879-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-04-05 | — | — | US | disclosed |
| US-20180093994-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-04-05 | — | — | US | disclosed |
| US-9932347-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9925169-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20170334922-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2017-11-23 | — | — | US | disclosed |
| US-20170333395-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11427585-B2 | Spiro-lactam NMDA modulators and methods of using same | GRIN1, GRIN2A, GRIN2C | SYK 2213/4885PPARA 1901/4885MMP9 4064/4885 |
| US-20180093994-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | SYK 1578/4885PPARA 1186/4885MMP9 3466/4885 |
| US-11370790-B2 | Spiro-lactam NMDA modulators and methods of using same | GRIN1, GRIN2A, GRIN2C | SYK 2213/4885PPARA 1901/4885MMP9 4064/4885 |
| US-10196401-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | SYK 1578/4885PPARA 1186/4885MMP9 3466/4885 |
| US-10150769-B2 | Spiro-lactam NMDA modulators and methods of using same | GRIN1, GRIN2A, GRIN2C | SYK 2213/4885PPARA 1901/4885MMP9 4064/4885 |
| US-20180291023-A1 | SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME | GRIN1, GRIN2A, GRIN2C | SYK 2213/4885PPARA 1901/4885MMP9 4064/4885 |
| US-20170333395-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | SYK 1531/4885PPARA 1244/4885MMP9 3472/4885 |
| US-20230128006-A1 | SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME | GRIN1, GRIN2A, GRIN2C | SYK 2213/4885PPARA 1901/4885MMP9 4064/4885 |
| US-10195179-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | SYK 1531/4885PPARA 1244/4885MMP9 3472/4885 |
| US-20170334922-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | SYK 1578/4885PPARA 1186/4885MMP9 3466/4885 |
| US-20180092879-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | SYK 1531/4885PPARA 1244/4885MMP9 3472/4885 |
| US-20230192693-A1 | SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME | GRIN1, GRIN2A, GRIN2C | SYK 2213/4885PPARA 1901/4885MMP9 4064/4885 |
| US-12084444-B2 | Spiro-lactam NMDA modulators and methods of using same | GRIN1, GRIN2A, GRIN2C | SYK 2213/4885PPARA 1901/4885MMP9 4064/4885 |
| US-20250002495-A1 | SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME | GRIN1, GRIN2A, GRIN2C | SYK 2213/4885PPARA 1901/4885MMP9 4064/4885 |
| US-12157736-B2 | Spiro-lactam NMDA modulators and methods of using same | GRIN1, GRIN2A, GRIN2C | SYK 2213/4885PPARA 1901/4885MMP9 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.